{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Viet CT"],"funding":["NIDCR NIH HHS","Oral and Maxillofacial Surgery Foundation"],"pagination":["42"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8178935"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["<h4>Background</h4>Oral squamous cell carcinoma (OSCC) is a capricious cancer with poor survival rates, even for early-stage patients. There is a pressing need to develop more precise risk assessment methods to appropriately tailor clinical treatment. Genome-wide association studies have not produced a viable biomarker. However, these studies are limited by using heterogeneous cohorts, not focusing on methylation although OSCC is a heavily epigenetically-regulated cancer, and not combining molecular data with clinicopathologic data for risk prediction. In this study we focused on early-stage (I/II) OSCC and created a risk score called the REASON score, which combines clinicopathologic characteristics with a 12-gene methylation signature, to predict the risk of 5-year mortality.<h4>Methods<"],"journal":["Biomarker research"],"pubmed_title":["The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma."],"pmcid":["PMC8178935"],"funding_grant_id":["K23 DE030250"],"pubmed_authors":["McGue CM","Asam K","Cheng AC","Viet CT","Couey MA","Thomas CM","Doan C","Yu G","Kilkuts CA","Lee SC","Grandhi A","Aouizerat BE","Callahan NF","Nguyen K","Wongworawat YC","Philipone E","Walker PC","Yoon AJ","Patel AA","Kidd SC","Allen CT","Ricks OL","Haghighiabyaneh M"],"additional_accession":[]},"is_claimable":false,"name":"The REASON score: an epigenetic and clinicopathologic score to predict risk of poor survival in patients with early stage oral squamous cell carcinoma.","description":"<h4>Background</h4>Oral squamous cell carcinoma (OSCC) is a capricious cancer with poor survival rates, even for early-stage patients. There is a pressing need to develop more precise risk assessment methods to appropriately tailor clinical treatment. Genome-wide association studies have not produced a viable biomarker. However, these studies are limited by using heterogeneous cohorts, not focusing on methylation although OSCC is a heavily epigenetically-regulated cancer, and not combining molecular data with clinicopathologic data for risk prediction. In this study we focused on early-stage (I/II) OSCC and created a risk score called the REASON score, which combines clinicopathologic characteristics with a 12-gene methylation signature, to predict the risk of 5-year mortality.<h4>Methods<","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-26T15:35:54.143Z","creation":"2022-02-10T14:06:36.2Z"},"accession":"S-EPMC8178935","cross_references":{"pubmed":["34090518"],"doi":["10.1186/s40364-021-00292-x"]}}